Published in:
01-12-2020 | Breast Cancer | ASO Author Reflections
ASO Author Reflections: Core Needle Biopsy and Hormonal Receptor Retesting in Breast Cancer: Controversy and Management
Authors:
Siji Zhu, MD, Xiaosong Chen, MD, PhD, Kunwei Shen, MD, PhD
Published in:
Annals of Surgical Oncology
|
Special Issue 3/2020
Login to get access
Excerpt
Core needle biopsy (CNB), which is accurate, convenient, and cost-effective, has been widely used for breast cancer diagnosis, and results obtained from CNB samples have important effects on treatment plans. However, the concordance rate of hormonal receptor (HR), Ki67, and human epidermal growth factor receptor 2 (HER2) testing between CNB and the following surgical sample (FSS) remains controversial, often challenged about small specimen volume, lack of total tumor representation, and uneven receptor distributions in CNB specimens.
1 The HR is used as a decisive marker to guide the decision to use adjuvant treatment, especially endocrine treatment, and to predict disease prognosis. For patients with a discordant HR between CNB and FSS, data about their optimal clinical management still are lacking. Therefore, this study was conducted to investigate the clinicopathologic features, adjuvant treatment choice, and disease outcome among patients with different HR statuses between CNB and FSS. …
